Literature DB >> 15168157

Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus.

Ken-ichi Hoshi1, Masayuki Matsuda, Mariko Ishikawa, Shigeaki Mitsuhashi, Takahisa Gono, Takao Hashimoto, Shu-ichi Ikeda.   

Abstract

We report a patient with systemic lupus erythematosus (SLE) who developed fulminant pulmonary hemorrhage. This patient also showed liver dysfunction, bicytopenia and hyperferritinemia, with an increase in serum levels of interleukin (IL)-1 beta, IL-6 and tumor necrosis factor-alpha (TNF-alpha) at the onset of pulmonary symptoms, probably indicating an associated hemophagocytic syndrome. Despite an acute progressive course temporarily requiring mechanical ventilation the patient was successfully treated with continuous drip infusion of tacrolimus, plasmapheresis and intravenous high-dose immunoglobulin and corticosteroid. In this patient increased inflammatory cytokines ascribable to activation of macrophages and/or helper T cells were considered to play an important role in the pathogenesis of the pulmonary hemorrhage. Because this complication is frequently fatal in SLE, intensive therapy, including immunosuppressants and plasmapheresis, should be actively considered as early as possible after onset.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168157     DOI: 10.1007/s10067-003-0859-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

1.  Pregnancy in renal transplant patients.

Authors:  J I Moon; S G Park; K O Cheon; S I Kim; Y S Kim; Y W Park; K Park
Journal:  Transplant Proc       Date:  2000-11       Impact factor: 1.066

2.  FK-506 (tacrolimus) therapy for an unusual SLE-like disease.

Authors:  K Kilian; A Banyai; A Karadi; K Miklos; G G Patranyi; K Paloczi
Journal:  Transplant Proc       Date:  1998-12       Impact factor: 1.066

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; S P Lan; R D Rohde; J M Lachin
Journal:  N Engl J Med       Date:  1992-05-21       Impact factor: 91.245

5.  Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study.

Authors:  K Manger; J R Kalden; B Manger
Journal:  Br J Rheumatol       Date:  1996-07

6.  Adult respiratory distress syndrome in systemic lupus erythematosus: causes and prognostic factors: a single center, retrospective study.

Authors:  W U Kim; S I Kim; W H Yoo; J H Park; J K Min; S C Kim; Y S Hong; S H Lee; S H Park; C S Cho; H Y Kim
Journal:  Lupus       Date:  1999       Impact factor: 2.911

Review 7.  Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management.

Authors:  R J Green; S J Ruoss; S A Kraft; S R Duncan; G J Berry; T A Raffin
Journal:  Chest       Date:  1996-11       Impact factor: 9.410

8.  Adult respiratory distress syndrome caused by acute systemic lupus erythematosus.

Authors:  P Domingo-Pedrol; A Rodriguez de la Serna; J Mancebo-Cortes; J M Sanchez-Segura
Journal:  Eur J Respir Dis       Date:  1985-08

Review 9.  Treatment of hemorrhagic lupus pneumonitis with plasmapheresis.

Authors:  R W Erickson; W A Franklin; W Emlen
Journal:  Semin Arthritis Rheum       Date:  1994-10       Impact factor: 5.532

10.  Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations.

Authors:  M Yasuhara; T Hashida; M Toraguchi; Y Hashimoto; M Kimura; K Inui; R Hori; Y Inomata; K Tanaka; Y Yamaoka
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

View more
  7 in total

Review 1.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

2.  Prompt plasmapheresis successfully rescue pulmonary-renal syndrome caused by ANCA-negative microscopic polyangiitis.

Authors:  Chih-Chiang Wang; Jeng-Chuan Shiang; Ming-Kai Tsai; I-Hung Chen; Shih-Hua Lin; Pauling Chu; Chia-Chao Wu
Journal:  Clin Rheumatol       Date:  2009-08-28       Impact factor: 2.980

3.  Diffuse alveolar hemorrhage: a rare life-threatening condition in systemic lupus erythematosus.

Authors:  Ravi Paul Singh Virdi; Adeel Bashir; Ghulamullah Shahzad; Javed Iqbal; Jose O Mejia
Journal:  Case Rep Pulmonol       Date:  2012-05-27

4.  Intravenous immunoglobulin in the management of lupus nephritis.

Authors:  Scott E Wenderfer; Trisha Thacker
Journal:  Autoimmune Dis       Date:  2012-09-27

5.  Tacrolimus as a reinforcement therapy for a patient with MPO-ANCA-associated diffuse alveolar hemorrhage.

Authors:  Satoko Kawasaki; Hideki Nakamura; Emi Honda; Nozomi Iwanaga; Atsushi Kawakami; Hiroaki Ida; Tomoki Origuchi; Shoko Honda; Yoshiko Tsuchihashi; Hiroyuki Yoshimine; Katsumi Eguchi
Journal:  Clin Rheumatol       Date:  2006-08-10       Impact factor: 3.650

6.  Treatment of diffuse alveolar hemorrhage in systemic lupus erythematosus patient with local pulmonary administration of factor VIIa (rFVIIa): a case report.

Authors:  Iehab B Alabed
Journal:  Medicine (Baltimore)       Date:  2014-09       Impact factor: 1.889

7.  Dramatic response to plasma exchange in systemic lupus erythematosus with acute complications: Report of two cases.

Authors:  Rekha Hans; Ratti Ram Sharma; Neelam Marwaha
Journal:  Indian J Crit Care Med       Date:  2013-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.